Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026 S4.3: prohibited at all times. Non-Specified. [1]
S4.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Clinical research
A randomized phase 2 trial enrolled 120 ambulatory boys aged six to under sixteen with Duchenne muscular dystrophy. Domagrozumab did not significantly improve the four-stair-climb endpoint or the reported secondary clinical endpoints compared with placebo. Most reported adverse events were mild and not considered treatment-related. [2]
- Abstract reviewed; findings apply to this DMD trial, not healthy athletes. No general safety or efficacy claim follows from tolerability in this setting.
What remains uncertain
- Current therapeutic authorization and consumer-product exposure were not established. The linked publication lists an erratum; detailed numerical efficacy claims are omitted.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- Randomized phase 2 domagrozumab trial in DMD ↗Accessed 2026-11-10 · Primary-study abstract and metadata
Abstract and bibliographic record
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.